<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ATRACURIUM BESYLATE</span><br/>(a-tra-kyoor'ee-um)<br/><span class="topboxtradename">Tracrium<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">skeletal muscle relaxant, nondepolarizing</span>; <span class="classification">neuromuscular blocker</span><br/><b>Prototype: </b>Tubocurarine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits neuromuscular transmission by binding competitively with acetylcholine to muscle end plate receptors. Lacks analgesic
         action and has no apparent effect on pain threshold, consciousness, or cerebration. Given in general anesthesia only after
         unconsciousness has been induced by other drugs.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Synthetic skeletal muscle relaxant pharmacologically similar to tubocurarine that produces shorter duration of neuromuscular
         blockade, exhibits minimal direct effects on cardiovascular system, and has less histamine-releasing action. Has minimal cumulative
         tendency with subsequent doses if recovery from the drug begins before dose is repeated.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct for general anesthesia to produce skeletal muscle relaxation during surgery; to facilitate endotracheal intubation.
         Especially useful for patients with severe renal or hepatic disease, limited cardiac reserve, and in patients with low or
         atypical pseudocholinesterase levels.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Myasthenia gravis. Safety during pregnancy (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>When appreciable histamine release would be hazardous (as in asthma or anaphylactoid reactions, significant cardiovascular
         disease), neuromuscular disease (e.g., Eaton-Lambert syndrome), carcinomatosis, electrolyte or acidbase imbalances,
         dehydration, impaired pulmonary function.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Skeletal Muscle Relaxation</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> <img src="../images/special/greaterorequal.gif"/><i>2 y</i>, 0.40.5 mg/kg initial dose, then 0.080.1 mg/kg 2045 min after the first dose if necessary, reduce doses
               if used with general anesthetics<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>1 mo2 y</i>, 0.30.4 mg/kg<br/><br/><span class="indicationtitle">Mechanical Ventilation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 59 mcg/kg/min by continuous infusion<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Verify correct concentration and rate of infusion for infants and children with physician.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give initial bolus dose undiluted.  <span class="methodtype">Continuous:</span> Maintenance dose must be diluted with NS, D5W or D5/NS. Do not mix in same syringe or administer through same needle as used
                  for alkaline solutions [incompatible with alkaline solutions (e.g., barbiturates)].  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give as bolus dose.  <span class="methodtype">Continuous:</span> Give infusion.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 2°8° C (36°46° F) to preserve potency unless otherwise directed. Avoid freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Bradycardia, tachycardia. <span class="typehead"> Respiratory:</span>
<span class="speceff-life">Respiratory depression</span>. <span class="typehead">Other:</span> Increased salivation, <span class="speceff-life">anaphylaxis</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">general anesthetics</span> increase magnitude and duration of neuromuscular blocking action; <span class="classification">aminoglycosides</span>, <b>bacitracin,</b>
<b>polymyxin B,</b>
<b>clindamycin,</b>
<b>lidocaine,</b>
<b>parenteral magnesium,</b>
<b>quinidine,</b>
<b>quinine,</b>
<b>trimethaphan,</b>
<b>verapamil</b> increase neuromuscular blockade; <span class="classification">diuretics</span> may increase or decrease neuromuscular blockade; <b>lithium</b> prolongs duration of neuromuscular blockade; <span class="classification">narcotic analgesics</span> present possibility of additive respiratory depression; <b>succinylcholine</b> increases onset and depth of neuromuscular blockade; <b>phenytoin</b> may cause resistance to or reversal of neuromuscular blockade. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span> 2 min. <span class="typehead">Peak:</span> 35 min. <span class="typehead">Duration:</span> 6070 min. <span class="typehead">Distribution:</span> Well distributed to tissues and extracellular fluids; crosses placenta; distribution into breast milk unknown. <span class="typehead">Metabolism:</span> Rapid nonenzymatic degradation in bloodstream. <span class="typehead">Elimination:</span> 7090% excreted in urine in 57 h. <span class="typehead">Half-Life:</span> 20 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline serum electrolytes, acidbase balance, and renal function as part of preanesthetic assessment.</li>
<li>
            							Note: Personnel and equipment required for endotracheal intubation, administration of oxygen under positive pressure, artificial
            respiration, and assisted or controlled ventilation must be immediately available.
            						
         </li>
<li>Evaluate degree of neuromuscular blockade and muscle paralysis to avoid risk of overdosage by qualified individual using peripheral
            nerve stimulator.
         </li>
<li>Monitor BP, pulse, and respirations and evaluate patient's recovery from neuromuscular blocking (curare-like) effect as evidenced
            by ability to breathe naturally or to take deep breaths and cough, keep eyes open, lift head keeping mouth closed, adequacy
            of hand-grip strength. Notify physician if recovery is delayed.
         </li>
<li>
            							Note: Recovery from neuromuscular blockade usually begins 3545 min after drug administration and is almost complete in about
            1 h. Recovery time may be delayed in patients with cardiovascular disease, edematous states, and in older adults.
            						
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>